PeptideDB

Betamethasone

CAS: 378-44-9 F: C22H29FO5 W: 392.46

Betamethasone is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive activities. Betamethasone accel
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity Betamethasone is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive activities. Betamethasone accelerates fetal lung maturation and induces gene expression and apoptosis[1][2][3][4].
Invitro Betamethasone (0.1-1 μM; 12 h) induces gene expression in L929 cells[4].Betamethasone (0.1-1 μM; 48 h) induces CEM C7 T-cells apoptosis[4].
In Vivo Betamethasone (0.48 mg; i.v.gtt for 48 h) decreases the hypercapnia-induced increase in CBF due to decreased cerebral vasodilatation[1].Betamethasone (0.05 ml (1 mg/L); topical injection) ameliorates spinal nerve transection induced mechanical allodynia and thermal hyperalgesia, and reduces the activation of NF-κB and elevation of TNFα and IL-1β, and induces the expression of IL-10 in the rats brain[2]. Animal Model:
Name Betamethasone
CAS 378-44-9
Formula C22H29FO5
Molar Mass 392.46
Appearance Solid
Transport Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Reference [1]. Schwab M, et, al. Effects of betamethasone administration to the fetal sheep in late gestation on fetal cerebral blood flow. J Physiol. 2000 Nov 1;528(Pt 3):619-32. [2]. Xie W, et, al. Betamethasone affects cerebral expressions of NF-kappaB and cytokines that correlate with pain behavior in a rat model of neuropathy. Ann Clin Lab Sci. Winter 2006;36(1):39-46. [3]. Kubin ME, et, al. Clinical Efficiency of Topical Calcipotriol/Betamethasone Treatment in Psoriasis Relies on Suppression of the Inflammatory TNFα - IL-23 - IL-17 Axis. Acta Derm Venereol. 2017 Apr 6;97(4):449-455. [4]. Hofmann TH, et, al. Various glucocorticoids differ in their ability to induce gene expression, apoptosis and to repress NF-kappaB-dependent transcription. FEBS Lett. 1998 Dec 28;441(3):441-6.